Peptidomimetics and metalloprotease inhibitors as anticancer drugs

@inproceedings{Li2009PeptidomimeticsAM,
  title={Peptidomimetics and metalloprotease inhibitors as anticancer drugs},
  author={Su Li and XU WenFang},
  year={2009}
}
  • Su Li, XU WenFang
  • Published 2009
Peptidomimetics with three types, as the structural or functional mimetics of natural active peptides, can preserve the bioactivity and improve the bioavailability and the specificity towards the targets of the lead peptides. Peptidomimetics of high bioactivity can be designed through various ways including conformation restriction, modification and non-peptide design. Recently the concentration on the development of cancer chemotherapeutic drugs was transferred from cytotoxic drugs to target… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 62 references

Synthesis and biological evaluation of a new series of histone Deacetylases inhibitors

  • J Jiao, Q Wang, H Zhu, H Fang, W Xu
  • Chinese Chem Lett
  • 2008

The emerging role of lapatinib in HER 2positive breast cancer

  • A Ulhoa-Cintra, L Greenberg, E. GeyerC
  • Curr Oncol Rep
  • 2008

A phase II and pharmacological study of the matrix metalloproteinase inhibitor ( MMPI ) COL3 in patients with advanced soft tissue sarcomas

  • C ChuQS, B Forouzesh, +5 authors K. RowinskyE
  • Invest New Drugs
  • 2007

Similar Papers

Loading similar papers…